← Leaderboards
Laijun Lai
University Of Connecticut Storrs
$5,623,060
Attributed
$5,623,060
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $941.2K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,623,060 · 5
By mechanism
R01$3,301,173 · 2
R33$1,439,340 · 1
R21$882,547 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Connecticut Storrs
Same institution · by research overlap
- Andrew J Wiemer$4,146,227
- Raman Bahal$2,703,154
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroAntigensImmune ResponseT-LymphocyteCellsAutoantigensIn VivoArchitectureOrganThymus GlandT-Cell DevelopmentThymic Epithelial CellImmune TolerancePlayPreventLeadImmune SystemAutoimmune DiseasesGenerationsMediatingAutoreactive T CellAge RelatedPathogenesisLaboratories
Grant awards (15)
Treating T cell immunodeficiency among older adults by a recombinant Foxn1 fusion protein$473,340
R33 · FY2025 · AG · contact PI
Modeling and treating T cell immunodeficiency in CHARGE syndrome by ESC- and iPSC-derived thymic epithelial cells$438,967
R01 · FY2025 · AI · contact PI
Treating T cell immunodeficiency among older adults by a recombinant Foxn1 fusion protein$483,000
R33 · FY2024 · AG · contact PI
Modeling and treating T cell immunodeficiency in CHARGE syndrome by ESC- and iPSC-derived thymic epithelial cells$458,197
R01 · FY2024 · AI · contact PI
Treating T cell immunodeficiency among older adults by a recombinant Foxn1 fusion protein$483,000
R33 · FY2023 · AG · contact PI
Modeling and treating T cell immunodeficiency in CHARGE syndrome by ESC- and iPSC-derived thymic epithelial cells$455,109
R01 · FY2023 · AI · contact PI
The effects of BTNL2 on experimental autoimmune encephalomyelitis$201,250
R21 · FY2022 · AI · contact PI
Treating T cell immunodeficiency among older adults by a recombinant Foxn1 fusion protein$198,297
R21 · FY2022 · AG · contact PI
Treating T cell immunodeficiency among older adults by a recombinant Foxn1 fusion protein$241,500
R21 · FY2021 · AG · contact PI
The effects of BTNL2 on experimental autoimmune encephalomyelitis$241,500
R21 · FY2021 · AI · contact PI
Transplantation of ESC-derived thymic epithelial progenitors expressing autoantigen(s) ameliorating experimental autoimmune encephalomyelitis$395,000
R01 · FY2020 · AI · contact PI
Transplantation of ESC-derived thymic epithelial progenitors expressing autoantigen(s) ameliorating experimental autoimmune encephalomyelitis$395,000
R01 · FY2019 · AI · contact PI
Transplantation of ESC-derived thymic epithelial progenitors expressing autoantigen(s) ameliorating experimental autoimmune encephalomyelitis$395,000
R01 · FY2018 · AI · contact PI
Transplantation of ESC-derived thymic epithelial progenitors expressing autoantigen(s) ameliorating experimental autoimmune encephalomyelitis$395,000
R01 · FY2017 · AI · contact PI
Transplantation of ESC-derived thymic epithelial progenitors expressing autoantigen(s) ameliorating experimental autoimmune encephalomyelitis$368,900
R01 · FY2016 · AI · contact PI